{
    "symbol": "ATAI",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-16 14:02:06",
    "content": " So coming back to treatment resistant depression, I guess I\u2019m wondering as you think about your VLS-01 program, Viridia investment, the buccal transmucosal film, which contains DMT \u2013 for TRD, I guess I\u2019m wondering how is Atai thinking about short versus long-acting psychedelics and that experience and the importance of that for really driving good therapeutic benefit and really considering it relative to kind of the emerging treatment landscape with Compass and some other companies out there."
}